58.48
前日終値:
$58.57
開ける:
$58.43
24時間の取引高:
4.33M
Relative Volume:
1.34
時価総額:
$7.42B
収益:
$638.78M
当期純損益:
$-22.66M
株価収益率:
-335.32
EPS:
-0.1744
ネットキャッシュフロー:
$122.18M
1週間 パフォーマンス:
+22.19%
1か月 パフォーマンス:
+36.86%
6か月 パフォーマンス:
+205.38%
1年 パフォーマンス:
+375.06%
10 X Genomics Inc Stock (TXG) Company Profile
名前
10 X Genomics Inc
セクター
電話
(925) 401-7300
住所
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
TXG
10 X Genomics Inc
|
58.48 | 5.83B | 638.78M | -22.66M | 122.18M | -0.1744 |
|
VEEV
Veeva Systems Inc
|
236.58 | 31.59B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
57.89 | 14.13B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
TEM
Tempus Ai Inc
|
55.69 | 7.73B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
HQY
Healthequity Inc
|
105.57 | 8.28B | 1.34B | 230.70M | 440.96M | 2.6695 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-12-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 開始されました | Piper Sandler | Neutral |
| 2025-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 開始されました | Leerink Partners | Outperform |
| 2024-07-22 | アップグレード | Jefferies | Hold → Buy |
| 2024-07-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-10 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-06-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-05-01 | ダウングレード | TD Cowen | Buy → Hold |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-10 | 開始されました | Barclays | Overweight |
| 2023-03-31 | 開始されました | Stephens | Overweight |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2022-12-14 | 開始されました | Deutsche Bank | Buy |
| 2022-08-18 | ダウングレード | Goldman | Neutral → Sell |
| 2022-07-25 | 開始されました | Canaccord Genuity | Buy |
| 2022-07-15 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-07-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-09-14 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-15 | 開始されました | William Blair | Outperform |
| 2020-12-02 | 開始されました | Goldman | Neutral |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-10 | 開始されました | Stifel | Buy |
| 2020-03-05 | 開始されました | Guggenheim | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-10-07 | 開始されました | BofA/Merrill | Buy |
| 2019-10-07 | 開始されました | Cowen | Outperform |
| 2019-10-07 | 開始されました | JP Morgan | Overweight |
| 2019-09-24 | 開始されました | Evercore ISI | Outperform |
すべてを表示
10 X Genomics Inc (TXG) 最新ニュース
10x Genomics, Inc. (TXG) Stock Analysis: Navigating the High Valuation and Market Dynamics - DirectorsTalk Interviews
Is 10x Genomics Inc (TXG) Overvalued After 12.3% Rally? GF Value - GuruFocus
10x Genomics, Inc. (TXG) stock price, news, quote and history - Yahoo Finance UK
10x Genomics (NASDAQ:TXG) Trading Up 7.1%Time to Buy? - MarketBeat
TXG Stock Jumps As Earnings Beat Triggers Analyst Upgrades - stockstotrade.com
10X GENOMICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $60 FROM $50 - Bitget
10x Genomics Stock Jumps As Analysts Hike Price Targets - timothysykes.com
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG - TradingView
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
TXG Jumps As 10x Genomics Price Targets Surge After Q2 Beat - timothysykes.com
10X Genomics Inc (TXG) Stock News Today - TradingKey
10x Genomics, Inc. Stock 12‑Month Price Target Raised to $47.23, Implies 4% Upside - TradingView
10x Genomics Q2 Earnings Call Highlights - MarketBeat
10x Genomics stock hits 52-week high at 50.36 USD - Investing.com
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up - finance.yahoo.com
10X GENOMICS, INC. : JEFFERIES RAISES TARGET PRICE TO $53 FROM $40 - moomoo.com
10x Genomics, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash - Stock Titan
10x Genomics, Inc. 2026: Revenue $151.04M, EPS ($0.14) — 10-Q Summary - TradingView
10x Genomics $TXG Shares Sold by Janus Henderson Group PLC - MarketBeat
TXG|10X Genomics Inc|Price:58.260|Chg%:+6.230 - TradingKey
Has 10x Genomics Inc (TXG) Missed Earnings Expectations with Q2 - GuruFocus
10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Earnings call transcript: 10x Genomics tops Q2 2026 estimates, shares fall - Investing.com
Transcript : 10x Genomics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
10x Genomics Inc (TXG) Shares Fall 3.9% -- What GF Score of 58 T - GuruFocus
10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations - finance.yahoo.com
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - finance.yahoo.com
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
10x Genomics falls 2% despite beating revenue estimates - Investing.com
10x Genomics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
(TXG) 10x Genomics Now Expects 2026 Revenue Range $610M-$630M, vs. FactSet Est of $613.7M - marketscreener.com
Q2 2026 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics Q2 2026: Revenue $151.0M, Gross Margin 74%, Raises 2026 Revenue Guide - TradingView
10x Genomics: Q2 Earnings Snapshot - AOL.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q2 Revenue $151.0M, vs. FactSet Est of $146.7M - marketscreener.com
10x Genomics (NASDAQ: TXG) swings to Q2 loss but lifts 2026 revenue guide - Stock Titan
10x Genomics Reports Second Quarter 2026 Financial Results - marketscreener.com
10x Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
10X Genomics faces earnings test as revenue expected to decline By Investing.com - Investing.com Nigeria
10x Sued Over Spatial Genomics Patents by Caltech, Licensee (1) - Bloomberg Law News
10x Genomics (TXG) 10K Form and Latest SEC Filings 2026 - MarketBeat
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
10x Genomics, Inc. (TXG) - DirectorsTalk Interviews
58,083 Shares in 10x Genomics $TXG Acquired by Edgestream Partners L.P. - MarketBeat
Lazard Asset Management LLC Sells 45,761 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics (TXG) Teams Up With Lausanne Hospital To Push Cancer Diagnostics Forward - finance.yahoo.com
Enterprise value to revenue forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10x Genomics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
10x Genomics $TXG Shares Sold by Renaissance Technologies LLC - MarketBeat
10 X Genomics Inc (TXG) 財務データ
収益
当期純利益
現金流量
EPS
10 X Genomics Inc (TXG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Jun 22 '26 |
Sale |
34.44 |
30,000 |
1,033,269 |
1,108,380 |
| SULIMAN SHEHNAAZ | Director |
Jun 16 '26 |
Sale |
32.63 |
5,723 |
186,756 |
31,722 |
大文字化:
|
ボリューム (24 時間):